RLMD / Relmada Therapeutics, Inc.'s (RLMD) CEO Sergio Traversa on Q1 2022 Results - Earnings Call Transcript

Phase 3 trial failures were due to abnormally high placebo responses driven by poor trial design, enrollment, and oversight. REL-1017's underlying eff more_horizontal

Low-dose psilocybin generated s tatistically significant reduc tions in liver fat content, plasma glucose levels and body weight gain in a mice model more_horizontal

Relmada's (RLMD) shares rise on long-term efficiency and safety data from the phase III study of its lead candidate REL-1017 to treat patients with ma more_horizontal

Relmada Therapeutics has provided updates on its phase 3 program of esmethadone (REL-1017) as an adjunct in major depressive disorder. An interim anal more_horizontal

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advisor more_horizontal

CORAL GABLES, Fla. , May 8, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of more_horizontal

Relmada Therapeutics, Inc. (NASDAQ:RLMD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Tim McCarthy - LifeSci Advis more_horizontal

Shares of Relmada Therapeutics Inc. RLMD, -0.95% tumbled about 40% in premarket trading on Thursday, the day after the company said its experimental d more_horizontal